Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients

Neurological Sciences

Volumn 29, Issue SUPPL. 2, 2008, Pages

  Capobianco, Marco ^a   Rizzo, Annalisa ^b   Malucchi, Simona ^a   Sperli, Francesca ^a   Di Sapio, Alessia ^a   Oggero, Alessandra ^a   Zaffaroni, Mauro ^b   Ghezzi, Angelo ^b   Bertolotto, Antonio ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b Centro Studi Sclerosi Multipla   (Italy)

Author keywords

Glatiramer acetate; Interferon beta; Neutralising antibody

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ACTIVITY; HUMAN; MULTIPLE SCLEROSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY;

ANTIBODIES; CENTRAL NERVOUS SYSTEM; DRUG RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME; TREATMENT OUTCOME;

EID: 53649084967     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-008-0945-y     Document Type: Article

References (10)

1. Bertolotto A, Malucchi S, Sala A et al (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: A follow-up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148-153
2. Bellomi F, Scagnolari C, Tomassini V et al (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215:3-8
3. Gilli F, Bertolotto A, Sala A et al (2004) Neutralizing antibodies against IFN-b in multiple sclerosis: Antagonization of IFN-b mediated suppression of MMPs. Brain 127:259-268
4. Gilli F, Marnetto F, Caldano M et al (2006) Biological markers of interferon-beta therapy: Comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 12:1-11
5. Sorensen PS, Ross C, Klemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1191
6. Sorensen PS, Deisenhammer F, Duda P et al (2005) Guidelines on use of anti-IFN-b antibody measurements in multiple sclerosis: Report of an EFNS Task Force on IFNβ antibodies in multiple sclerosis. Eur J Neurol 12:817-827
7. Rovaris M, Comi G, Rocca MA et al (2007) Long-term follow-up of patients treated with glatiramer acetate: A multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler 13:502-508
8. Caon C, Din M, Ching W et al (2006) Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 13:471-474
9. Carrà A, Onaha P, Luetic G et al (2008) Therapeutic outcomes 3 years after switching of immunomodulatory therapies in patients with relapsing remitting multiple sclerosis in Argentina. Eur J Neurol 15:386-393
10. Pozzilli C, Antonini G, Bagnato F et al (2002) Monthly corticosteroids decrease neutralizing antibodies to IFN-beta1 b: A randomized trial in multiple sclerosis. J Neurol 249:50-56